CYP27A1 (Q02318) variants and mutations
CYP27A1 (also known as Q02318) is a human protein-coding gene encoding a sterol 26-hydroxylase, mitochondrial protein. It hydroxylates sterol intermediates in bile-acid synthesis and contributes to cholesterol elimination and oxysterol production. Biallelic loss-of-function variants cause cerebrotendinous xanthomatosis, a treatable disorder with cholestanol accumulation, cataracts, tendon xanthomas, and progressive neurologic disease. This analysis covers 1,107 CYP27A1 variants and mutations. Of these, 83% have computational variant effect predictions. Disease context includes cerebrotendinous xanthomatosis, Abnormality of the cardiovascular system, and Senior-Loken syndrome 1. Example CYP27A1 variants include M1T, M1V, and A2T.
Variant analysis overview
- Gene: CYP27A1
- Protein: Q02318
- UniProt accession: Q02318
- Organism: Homo sapiens
- Variants analyzed: 1107
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 819 unspecified-consequence records; 23 frameshift variants; 138 missense variants; 107 synonymous variants; 3 stop-gained variants; 5 in-frame deletions; 3 splice-region variants; 9 substitution
- Prediction scores: 920 variants have prediction scores (83% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: cerebrotendinous xanthomatosis, Abnormality of the cardiovascular system, Senior-Loken syndrome 1, photosensitive epilepsy, Seizure, placental retention, Intellectual disability, Abnormality of the skeletal system, Premature coronary artery atherosclerosis, breast cancer, neoplasm, colorectal carcinoma.
Protein structure and variant hotspots
- Protein features: 1 binding sites; 3 post-translational modification sites.
- PTM context: 3 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable CYP27A1 variants
Examples include M1T, M1V, A2T, A2V, A2S, A2D, A2A, A3C. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1T (p.Met1Thr), rs759003992, ClinGen CA2112501, ClinVar RCV000286244, ClinVar RCV000351883, MetaLR 0.30, MetaSVM -0.65, Conflicting interpretations, CYP27A1-related disorder; Cholestanol storage disease; not provided
- M1V (p.Met1Val), rs1446633660, ClinGen CA350575144, ClinVar RCV000664683, MetaLR 0.27, MetaSVM -0.67, Likely pathogenic, Cholestanol storage disease
- A2T (p.Ala2Thr), TOPMed rs1943396546, REVEL 0.26, CADD 23.50
- A2V (p.Ala2Val), gnomAD rs1213986887, REVEL 0.26, CADD 23.30
- A2S (p.Ala2Ser), gnomAD 2-218782186-G-T, REVEL 0.19, CADD 23.10
- A2D (p.Ala2Asp), gnomAD 2-218782187-C-A, REVEL 0.35, CADD 23.20
- A2A (p.Ala2Ala), rs1265766070, gnomAD 2-218782188-T-G, CADD 14.90
- A3C (p.Ala3Cys), rs587778802, gnomAD 2-218782186-G-GC, CADD 28.50
- A3S (p.Ala3Ser), gnomAD 2-218782189-G-T, REVEL 0.13, CADD 17.90
- A3G (p.Ala3Gly), gnomAD 2-218782190-C-G, REVEL 0.11, CADD 23.20
- A3V (p.Ala3Val), gnomAD 2-218782190-C-T, REVEL 0.08, CADD 21.20
- A3A (p.Ala3Ala), rs971599666, gnomAD 2-218782191-G-T, CADD 12.40
- L4M (p.Leu4Met), gnomAD rs1187805203, REVEL 0.19, CADD 22.90, Uncertain significance, Cholestanol storage disease
- L4P (p.Leu4Pro), rs868195486, TOPMed rs868195486, gnomAD rs868195486, REVEL 0.44, CADD 24.00, Variant assessed as somatic; moderate impact.
- G5D (p.Gly5Asp), rs1943396793, ClinGen CA350575283, ClinVar RCV001866335, NCI-TCGA TCGA novel, AlphaMissense 0.20, MetaLR 0.21, Uncertain significance, Cholestanol storage disease
- G5S (p.Gly5Ser), Ensembl rs866045541
- G5R (p.Gly5Arg), gnomAD 2-218782185-G-GGC, CADD 27.10
- G5C (p.Gly5Cys), gnomAD 2-218782195-G-T, REVEL 0.19, CADD 15.60
- G5V (p.Gly5Val), gnomAD 2-218782196-G-T, REVEL 0.23, CADD 19.40
- G5G (p.Gly5Gly), gnomAD 2-218782197-C-A, CADD 13.60
- C6Y (p.Cys6Tyr), gnomAD rs1475867060, REVEL 0.21, CADD 18.30
- C6F (p.Cys6Phe), gnomAD 2-218782199-G-T, REVEL 0.17, CADD 19.40
- C6* (p.Cys6Ter), gnomAD 2-218782200-C-A, CADD 35.00
- C6C (p.Cys6Cys), gnomAD 2-218782200-C-T, CADD 14.90
- A7V (p.Ala7Val), rs1364383591, ClinGen CA350575341, ClinVar RCV001844522, ClinVar RCV002034725, REVEL 0.11, CADD 16.40, Uncertain significance, Cardiovascular phenotype; CYP27A1-related disorder; not specified
- A7T (p.Ala7Thr), gnomAD 2-218782201-G-A, REVEL 0.14, CADD 13.90
- A7S (p.Ala7Ser), gnomAD 2-218782201-G-T, REVEL 0.14, CADD 12.30
- A7G (p.Ala7Gly), rs1325993773, gnomAD 2-218782201-GC-G, CADD 23.30
- A7E (p.Ala7Glu), gnomAD 2-218782202-C-A, REVEL 0.27, CADD 16.60
- A7A (p.Ala7Ala), gnomAD 2-218782203-G-T, CADD 12.40
- R8K (p.Arg8Lys), Ensembl rs1943397005
- R8M (p.Arg8Met), gnomAD 2-218782205-G-T, REVEL 0.35, CADD 25.30
- R8S (p.Arg8Ser), gnomAD 2-218782206-G-T, REVEL 0.51, CADD 23.50
- R8R (p.Arg8Arg), rs1383705510, gnomAD 2-218782206-G-A, CADD 15.10
- L9P (p.Leu9Pro), rs2470201632, ClinGen CA350575385, ClinVar RCV002295799, Uncertain significance, Cholestanol storage disease
- L9A (p.Leu9Ala), rs1163340926, gnomAD 2-218782204-A-AG, CADD 32.00
- L9L (p.Leu9Leu), rs2106479038, gnomAD 2-218782207-C-T, CADD 13.60
- R10K (p.Arg10Lys), rs1943397146, ClinGen CA350575401, ClinVar RCV002686221, TOPMed rs1943397146, REVEL 0.14, CADD 23.60, Uncertain significance, Cholestanol storage disease
- R10G (p.Arg10Gly), gnomAD 2-218782210-A-G, REVEL 0.32, CADD 23.20
- R10M (p.Arg10Met), gnomAD 2-218782211-G-T, REVEL 0.33, CADD 24.00
- W11* (p.Trp11Ter), rs1398584213, ClinGen CA350575413, ClinVar RCV001907858, TOPMed rs1398584213, CADD 37.00, Pathogenic
- W11G (p.Trp11Gly), TOPMed rs1209215033, gnomAD rs1209215033, REVEL 0.27, CADD 23.30
- W11R (p.Trp11Arg), TOPMed rs1209215033, gnomAD rs1209215033, REVEL 0.22, CADD 22.80, Uncertain significance, Cholestanol storage disease
- W11L (p.Trp11Leu), gnomAD 2-218782214-G-T, REVEL 0.23, CADD 22.80
- W11C (p.Trp11Cys), gnomAD 2-218782215-G-C, REVEL 0.34, CADD 24.00
- A12E (p.Ala12Glu), Ensembl rs1943397340
- A12G (p.Ala12Gly), gnomAD 2-218782213-T-TG, CADD 28.20
- A12T (p.Ala12Thr), gnomAD 2-218782216-G-A, REVEL 0.13, CADD 21.70
- A12V (p.Ala12Val), gnomAD 2-218782217-C-T, REVEL 0.14, CADD 21.20
- A12A (p.Ala12Ala), rs764764261, gnomAD 2-218782218-G-A, CADD 15.10
- L13P (p.Leu13Pro), rs1243753558, ClinGen CA350575469, ClinVar RCV001884958, gnomAD rs1243753558, REVEL 0.36, CADD 22.90, Uncertain significance, Cholestanol storage disease
- L13M (p.Leu13Met), gnomAD 2-218782219-C-A, REVEL 0.26, CADD 24.70
- L13L (p.Leu13Leu), gnomAD 2-218782221-G-T, CADD 12.30
- R14Q (p.Arg14Gln), Ensembl rs1325577166, REVEL 0.11, CADD 20.30
- R14P (p.Arg14Pro), rs1224997517, gnomAD 2-218782218-GCTGC, CADD 29.00
- R14R (p.Arg14Arg), gnomAD 2-218782222-C-A, CADD 13.80
- R14L (p.Arg14Leu), gnomAD 2-218782223-G-T, REVEL 0.15, CADD 21.00
- G15E (p.Gly15Glu), TOPMed rs1406390308, gnomAD rs1406390308, REVEL 0.12, CADD 22.60
- G15V (p.Gly15Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G15R (p.Gly15Arg), gnomAD 2-218782225-G-A, REVEL 0.12, CADD 21.40
- G15G (p.Gly15Gly), rs988463082, gnomAD 2-218782227-G-A, CADD 11.70
- A16T (p.Ala16Thr), gnomAD rs1357293342, REVEL 0.07, CADD 12.20
- A16G (p.Ala16Gly), rs1413976755, gnomAD 2-218782224-A-AG, CADD 25.50
- A16R (p.Ala16Arg), rs1413976755, gnomAD 2-218782224-AGG-A, CADD 25.00
- A16S (p.Ala16Ser), gnomAD 2-218782228-G-T, REVEL 0.08, CADD 11.40
- A16V (p.Ala16Val), gnomAD 2-218782229-C-T, REVEL 0.13, CADD 8.79
- G17S (p.Gly17Ser), ExAC rs753177502, gnomAD rs753177502, REVEL 0.23, CADD 18.70
- G17C (p.Gly17Cys), gnomAD 2-218782228-GCCGG, CADD 29.20
- G17R (p.Gly17Arg), gnomAD 2-218782231-G-C, REVEL 0.19, CADD 19.10
- G17D (p.Gly17Asp), gnomAD 2-218782232-G-A, REVEL 0.25, CADD 17.10
- G17G (p.Gly17Gly), gnomAD 2-218782233-C-A, CADD 10.10
- R18C (p.Arg18Cys), rs1284837909, ClinGen CA350575567, ClinVar RCV003059263, TOPMed rs1284837909, REVEL 0.20, CADD 18.90, Uncertain significance, Cholestanol storage disease
- R18L (p.Arg18Leu), rs2106479070, ClinGen CA350575580, ClinVar RCV001844521, Ensembl rs2106479070, AlphaMissense 0.08, MetaLR 0.19, Uncertain significance, not specified
- R18S (p.Arg18Ser), TOPMed rs1284837909, gnomAD rs1284837909, REVEL 0.15, CADD 13.90, Uncertain significance
- R18G (p.Arg18Gly), gnomAD 2-218782234-C-G, REVEL 0.16, CADD 15.60
- R18H (p.Arg18His), gnomAD 2-218782235-G-A, REVEL 0.12, CADD 16.00
- R18R (p.Arg18Arg), rs1301969299, gnomAD 2-218782236-T-C, CADD 14.20
- G19A (p.Gly19Ala), rs1203579586, ClinGen CA350575596, ClinVar RCV002042561, TOPMed rs1203579586, AlphaMissense 0.10, MetaLR 0.39, Uncertain significance, Cholestanol storage disease
- G19D (p.Gly19Asp), TOPMed rs1203579586, gnomAD rs1203579586, REVEL 0.37, AlphaMissense 0.10, Uncertain significance
- G19S (p.Gly19Ser), rs758959471, ClinGen CA2112504, ClinVar RCV002344890, ClinVar RCV003096806, REVEL 0.33, CADD 23.70, Conflicting interpretations, Cholestanol storage disease; not provided; Cardiovascular phenotype
- G19V (p.Gly19Val), rs1203579586, ClinGen CA350575602, ClinVar RCV001983369, TOPMed rs1203579586, REVEL 0.43, AlphaMissense 0.10, Uncertain significance, Cholestanol storage disease
- G19G (p.Gly19Gly), gnomAD 2-218782239-C-T, CADD 9.59
- L20P (p.Leu20Pro), Ensembl rs1943398374, REVEL 0.42, CADD 25.60
- L20F (p.Leu20Phe), gnomAD 2-218782240-C-T, REVEL 0.28, CADD 23.50
- L20I (p.Leu20Ile), gnomAD 2-218782240-C-A, REVEL 0.24, CADD 23.20
- L20L (p.Leu20Leu), gnomAD 2-218782242-C-T, CADD 10.30
- C21R (p.Cys21Arg), rs751804153, ClinGen CA2112506, ClinVar RCV001924253, ExAC rs751804153, REVEL 0.08, CADD 15.60, Uncertain significance, Cholestanol storage disease
- C21W (p.Cys21Trp), rs781222632, ClinGen CA350575655, ClinVar RCV000730190, ClinVar RCV001844230, AlphaMissense 0.16, MetaLR 0.23, Uncertain significance, not specified; not provided
- C21Y (p.Cys21Tyr), rs757653354, ClinGen CA2112507, ClinVar RCV002041305, ExAC rs757653354, REVEL 0.31, CADD 16.40, Uncertain significance, Cholestanol storage disease
- C21* (p.Cys21Ter), gnomAD 2-218782245-C-A, CADD 32.00
- C21C (p.Cys21Cys), rs781222632, gnomAD 2-218782245-C-T, AlphaMissense 0.16, MetaLR 0.23
- P22L (p.Pro22Leu), NCI-TCGA Cosmic COSV5146, REVEL 0.29, CADD 15.70, Variant assessed as somatic; moderate impact.
- P22S (p.Pro22Ser), gnomAD 2-218782246-C-T, REVEL 0.07, CADD 12.60
- P22H (p.Pro22His), gnomAD 2-218782247-C-A, REVEL 0.25, CADD 22.40
- P22P (p.Pro22Pro), rs1423345815, gnomAD 2-218782248-C-T, CADD 3.52
- H23D (p.His23Asp), gnomAD rs1255948354, REVEL 0.13, CADD 6.99, Uncertain significance
- H23N (p.His23Asn), rs1255948354, ClinGen CA350575694, ClinVar RCV002369470, ClinVar RCV004793791, REVEL 0.08, CADD 4.89, Uncertain significance, Cardiovascular phenotype; not provided
- H23P (p.His23Pro), rs1943398664, ClinGen CA350575697, ClinVar RCV001965377, gnomAD rs1943398664, REVEL 0.14, CADD 0.10, Uncertain significance, Cholestanol storage disease
- H23R (p.His23Arg), rs1943398664, ClinGen CA350575701, ClinVar RCV001844523, gnomAD rs1943398664, REVEL 0.08, CADD 0.02, Uncertain significance, not specified
- H23T (p.His23Thr), gnomAD 2-218782244-GC-G, CADD 18.60
- H23Q (p.His23Gln), gnomAD 2-218782251-C-A, REVEL 0.07, CADD 2.19
- H23H (p.His23His), rs1444634924, gnomAD 2-218782251-C-T, CADD 4.22
- G24R (p.Gly24Arg), Ensembl rs1200489164, REVEL 0.08, CADD 16.00, Uncertain significance, Cholestanol storage disease
- G24W (p.Gly24Trp), gnomAD 2-218782252-G-T, REVEL 0.31, CADD 23.10
- G24V (p.Gly24Val), gnomAD 2-218782253-G-T, REVEL 0.18, CADD 16.60
- G24G (p.Gly24Gly), gnomAD 2-218782254-G-T, CADD 10.70
- A25G (p.Ala25Gly), rs2106479103, ClinGen CA350575751, ClinVar RCV001844520, Ensembl rs2106479103, AlphaMissense 0.08, MetaLR 0.19, Uncertain significance, not specified
- A25P (p.Ala25Pro), ExAC rs746125009, gnomAD rs746125009
- A25S (p.Ala25Ser), ExAC rs746125009, gnomAD rs746125009, REVEL 0.10, CADD 14.70, Uncertain significance, Cholestanol storage disease
- A25T (p.Ala25Thr), gnomAD 2-218782255-G-A, REVEL 0.06, CADD 15.20
- A25D (p.Ala25Asp), gnomAD 2-218782256-C-A, REVEL 0.35, CADD 23.30
- A25A (p.Ala25Ala), gnomAD 2-218782257-C-A, CADD 14.40
- R26K (p.Arg26Lys), rs192494481, ClinGen CA65813711, ClinVar RCV001911923, 1000Genomes rs192494481, REVEL 0.31, CADD 24.70, Uncertain significance, Cholestanol storage disease
- p.Arg26 Ala33del, rs1188925314, gnomAD 2-218782254-GGCCA, CADD 20.30
- R26I (p.Arg26Ile), gnomAD 2-218782259-G-T, REVEL 0.47, CADD 28.60
- A27G (p.Ala27Gly), gnomAD rs1159899670, REVEL 0.20, CADD 22.80
- A27V (p.Ala27Val), gnomAD rs1159899670, REVEL 0.24, CADD 23.90
- A27T (p.Ala27Thr), gnomAD 2-218782261-G-A, REVEL 0.06, CADD 19.00
- A27S (p.Ala27Ser), gnomAD 2-218782261-G-T, REVEL 0.13, CADD 18.40
- A27D (p.Ala27Asp), gnomAD 2-218782262-C-A, REVEL 0.36, CADD 25.80
- K28N (p.Lys28Asn), rs958713867, ClinGen CA65813717, ClinVar RCV001908012, gnomAD rs958713867, REVEL 0.20, CADD 23.30, Uncertain significance, Cholestanol storage disease
- K28R (p.Lys28Arg), ESP rs371449777, ExAC rs371449777, TOPMed rs371449777, gnomAD rs371449777, REVEL 0.21, CADD 24.90, Likely benign
- K28T (p.Lys28Thr), rs371449777, ClinGen CA2112510, ClinVar RCV000591741, ClinVar RCV001054067, REVEL 0.33, CADD 24.80, Uncertain significance, not provided; Cardiovascular phenotype; Cholestanol storage disease
- K28K (p.Lys28Lys), rs958713867, gnomAD 2-218782266-G-A, CADD 12.80
- A29G (p.Ala29Gly), Ensembl rs986737818
- A29T (p.Ala29Thr), rs1266912871, ClinGen CA350575803, ClinVar RCV002447983, ClinVar RCV003099986, REVEL 0.08, CADD 21.80, Uncertain significance, Cholestanol storage disease; Cardiovascular phenotype
- A29P (p.Ala29Pro), gnomAD 2-218782267-G-C, REVEL 0.43, CADD 23.40
- A29S (p.Ala29Ser), gnomAD 2-218782267-G-T, REVEL 0.06, CADD 20.40
- A29D (p.Ala29Asp), gnomAD 2-218782268-C-A, REVEL 0.41, CADD 22.80
- A29A (p.Ala29Ala), rs1310841339, gnomAD 2-218782269-C-T, CADD 13.50
- A30S (p.Ala30Ser), Ensembl rs990677310, Uncertain significance, Cholestanol storage disease
- A30T (p.Ala30Thr), gnomAD 2-218782270-G-A, REVEL 0.16, CADD 14.10
- A30E (p.Ala30Glu), gnomAD 2-218782271-C-A, REVEL 0.17, CADD 19.70
- A30V (p.Ala30Val), gnomAD 2-218782271-C-T, REVEL 0.10, CADD 20.30
- A30A (p.Ala30Ala), gnomAD 2-218782272-G-A, CADD 13.20
- I31T (p.Ile31Thr), gnomAD 2-218782274-T-C, REVEL 0.18, CADD 22.20
- I31I (p.Ile31Ile), gnomAD 2-218782275-C-A, CADD 12.90
- P32L (p.Pro32Leu), TOPMed rs1328145460, gnomAD rs1328145460, REVEL 0.30, CADD 23.80
- P32S (p.Pro32Ser), ExAC rs748087582, gnomAD rs748087582, REVEL 0.21, CADD 22.40
- P32T (p.Pro32Thr), gnomAD 2-218782276-C-A, REVEL 0.22, CADD 21.90
- P32H (p.Pro32His), gnomAD 2-218782277-C-A, REVEL 0.14, CADD 22.10
- A33T (p.Ala33Thr), rs1275043449, ClinGen CA350575897, ClinVar RCV001998020, TOPMed rs1275043449, REVEL 0.12, CADD 8.55, Uncertain significance, Cholestanol storage disease
- A33V (p.Ala33Val), gnomAD rs1335202761, REVEL 0.08, CADD 12.50
- A33S (p.Ala33Ser), gnomAD 2-218782279-G-T, REVEL 0.11, CADD 6.21
- A33D (p.Ala33Asp), gnomAD 2-218782280-C-A, REVEL 0.32, CADD 12.30
- A33A (p.Ala33Ala), rs967210940, gnomAD 2-218782281-C-T, CADD 5.71
- A34T (p.Ala34Thr), ExAC rs771972905, TOPMed rs771972905, gnomAD rs771972905, REVEL 0.04, CADD 14.60
- A34S (p.Ala34Ser), gnomAD 2-218782282-G-T, REVEL 0.04, CADD 13.00
- A34V (p.Ala34Val), gnomAD 2-218782283-C-T, REVEL 0.20, CADD 17.80
- A34D (p.Ala34Asp), gnomAD 2-218782283-C-A, REVEL 0.40, CADD 18.20
- A34A (p.Ala34Ala), rs773208703, gnomAD 2-218782284-C-T, CADD 9.48
- L35P (p.Leu35Pro), rs2106479125, ClinGen CA350575977, ClinVar RCV002003865, Ensembl rs2106479125, REVEL 0.37, CADD 18.70, Uncertain significance, Cholestanol storage disease
- L35I (p.Leu35Ile), gnomAD 2-218782285-C-A, REVEL 0.06, CADD 8.01
- L35F (p.Leu35Phe), gnomAD 2-218782285-C-T, REVEL 0.08, CADD 8.45
- L35L (p.Leu35Leu), rs1354685155, gnomAD 2-218782287-C-A, CADD 6.03
- P36L (p.Pro36Leu), gnomAD rs1233931786, REVEL 0.07, CADD 13.90
- P36T (p.Pro36Thr), gnomAD 2-218782288-C-A, REVEL 0.08, CADD 11.10
- P36P (p.Pro36Pro), gnomAD 2-218782290-C-A, CADD 5.98
- S37L (p.Ser37Leu), rs1559384559, ClinGen CA350576000, ClinVar RCV000735116, ClinVar RCV002477734, REVEL 0.09, AlphaMissense 0.12, Uncertain significance, not provided; Cholestanol storage disease
- S37W (p.Ser37Trp), rs1559384559, ClinGen CA350575998, ClinVar RCV001989345, ClinVar RCV004793682, AlphaMissense 0.12, MetaLR 0.18, Uncertain significance, not provided; Cholestanol storage disease
- S37A (p.Ser37Ala), gnomAD 2-218782291-T-G, REVEL 0.09, CADD 7.87
- S37* (p.Ser37Ter), gnomAD 2-218782292-C-A, CADD 32.00
- S37S (p.Ser37Ser), gnomAD 2-218782293-G-A, CADD 5.53
- D38V (p.Asp38Val), rs1201499588, ClinGen CA350576011, ClinVar RCV001926421, ClinVar RCV004044182, REVEL 0.09, CADD 15.80, Uncertain significance, not provided; Cholestanol storage disease; Cardiovascular phenotype
- D38E (p.Asp38Glu), gnomAD 2-218782296-C-G, REVEL 0.04, CADD 0.05
- K39* (p.Lys39Ter), rs2470201839, ClinGen CA350576025, ClinVar RCV003504062, Pathogenic
- K39M (p.Lys39Met), gnomAD 2-218782298-A-T, REVEL 0.17, CADD 15.80
- K39N (p.Lys39Asn), gnomAD 2-218782299-G-T, REVEL 0.06, CADD 9.98
- A40T (p.Ala40Thr), gnomAD rs1435517185, REVEL 0.06, CADD 9.92
- A40V (p.Ala40Val), NCI-TCGA Cosmic COSV5146, REVEL 0.07, CADD 10.30, Variant assessed as somatic; moderate impact.
- A40S (p.Ala40Ser), gnomAD 2-218782300-G-T, REVEL 0.06, CADD 8.14
- A40A (p.Ala40Ala), rs150389057, gnomAD 2-218782302-C-T, CADD 2.52
- T41A (p.Thr41Ala), gnomAD 2-218782303-A-G, REVEL 0.09, CADD 1.28
- T41T (p.Thr41Thr), gnomAD 2-218782305-C-A, CADD 5.09
- G42R (p.Gly42Arg), rs2106479143, ClinGen CA350576081, ClinVar RCV001892994, Ensembl rs2106479143, AlphaMissense 0.09, MetaLR 0.17, Uncertain significance, Cholestanol storage disease
- G42G (p.Gly42Gly), rs1238340088, gnomAD 2-218782308-A-G, CADD 8.36
- A43D (p.Ala43Asp), ExAC rs759232939, TOPMed rs759232939, gnomAD rs759232939, REVEL 0.11, CADD 13.60
- A43T (p.Ala43Thr), 1000Genomes rs558814935, ExAC rs558814935, gnomAD rs558814935, REVEL 0.05, CADD 14.70
- A43V (p.Ala43Val), ExAC rs759232939, TOPMed rs759232939, gnomAD rs759232939, REVEL 0.07, CADD 13.00, Uncertain significance, Cardiovascular phenotype
- A43S (p.Ala43Ser), gnomAD 2-218782309-G-T, REVEL 0.04, CADD 13.60
Public CYP27A1 analysis runs
- CYP27A1 analysis run — CYP27A1 (1,107 variants) — completed 2026-08-19